Pharmala Biotech (MDMA) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
31 Jul, 2026Executive summary
Achieved significant revenue growth and improved financial position compared to 2025, driven by strong sales and strategic transactions.
Executed a notable transaction with Jupiter Neuroscience, announced in Q3 and completed in Q4.
Financial highlights
Revenue for the nine months ended May 31, 2026 reached over $1,000,000, up from $338,000 year-over-year; Q3 revenue was $513,000 versus $135,000 in Q3 2025.
Net loss for Q3 2026 was $499,759, and for the nine months was $1,247,150, both improved from $524,235 and $1,814,110 in the prior year periods.
Cash used in operating activities for the nine months was $673,588, down from $748,758 year-over-year.
Outlook and guidance
Licensing agreements are expected to provide further revenue opportunities and reflect the potential value of ongoing R&D.
Latest events from Pharmala Biotech
- Revenue surged 10x year-over-year, with key patent and joint venture milestones achieved.MDMA
Q3 2024 - MDMA shipments and revenue rose, with operational gains and higher expenses from expansion.MDMAQ3 2025
- Customer deposits and clinical trial pipeline grew, driven by Australian regulatory approvals.MDMAQ1 2026
- Revenue up, losses down, and leadership changes mark a pivotal quarter in psychedelics commercialization.MDMAQ2 2026
- Customer deposits and clinical trial pipeline surged, fueled by Australian market expansion.MDMAQ4 2025
- Revenue surged 95% year-over-year, with operational gains and expanded distribution.MDMAQ2 2025
- MDMA therapy delivers rapid PTSD remission and global expansion, backed by innovation and strong IP.MDMASmall Cap Growth Virtual Investor Conference 2025
- Revenue surged 95% with improved EBITDA and a $1.56M private placement completed.MDMAQ4 2024
- Revenue up 95% with strong MDMA sales and new funding; distribution and U.S. growth drive outlook.MDMAQ1 2025